{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:33:21Z","timestamp":1794944001327,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intra-articular (IA) injection of hyaluronic acid (HA) (IA-HA) is a well-recognized treatment option for pain associated with symptomatic knee osteoarthritis (OA). IA-HA products differ in their HA content, molecular weight, cross-linking, and source of HA. These differences are assumed to affect the biocompatibility of the IA-HA products once injected inside the knee joint.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the present study, we investigated the biocompatibility of three multiple-injection IA-HA products available in the global market. These included SUPARTZ FX\u2122, a medium range molecular weight HA derived from rooster comb (Avian-HA); ORTHOVISC\u00ae, a high range molecular weight HA obtained through biological fermentation (Bio-HA); and SYNVISC\u00ae, a high molecular weight cross-linked hyaluronan derived from rooster comb (Avian-CL-HA). Rabbit knee joint tissues were histologically and biochemically examined after IA injection of the products. Furthermore, we compared the amounts of impurities in the IA-HA products.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>IA injection of Avian-CL-HA into rabbit knee joints induced the aggregation of inflammatory cells, infiltration of eosinophils, and an increase in the number of cells in the synovial fluid. However, these effects were not seen in the Avian-HA and Bio-HA groups. The residual protein content and the contaminant levels of bacterial endotoxins were below the limit of quantitation in all HA products. Avian-CL-HA contained relatively a large amount of (1\u2009\u2192\u20093)-\u03b2-D-glucan, but this was below the lower limit of quantification in the other HA products.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present results clearly demonstrate that the biocompatibility of Avian-HA is comparable to that of Bio-HA, and they were both considered to have a favorable safety profile for the treatment of symptomatic OA of the knee. However, immunostimulatory activity was observed after injection of Avian-CL-HA: this might be a result of its unique cross-linking structure and\/or the considerable amount of (1\u2009\u2192\u20093)-\u03b2-D-glucan impurity present in the formulation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-019-2815-6","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:05:49Z","timestamp":1568243149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Biocompatibility study of different hyaluronan products for intra-articular treatment of knee osteoarthritis"],"prefix":"10.1186","volume":"20","author":[{"given":"Keiji","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"2815_CR1","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1097\/01.blo.0000143938.30681.9d","volume":"427","author":"JA Buckwalter","year":"2004","unstructured":"Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004;427:S6\u201315.","journal-title":"Clin Orthop Relat Res"},{"key":"2815_CR2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163\u201396.","journal-title":"Lancet"},{"key":"2815_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0033-8389(03)00161-1","volume":"42","author":"DT Felson","year":"2004","unstructured":"Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin N Am. 2004;42:1\u20139.","journal-title":"Radiol Clin N Am"},{"issue":"Suppl 11","key":"2815_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/01.phm.0000245568.69434.1a","volume":"85","author":"SV Garstang","year":"2006","unstructured":"Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil. 2006;85(Suppl 11):S2\u2013S14.","journal-title":"Am J Phys Med Rehabil"},{"key":"2815_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","volume":"16","author":"W Zhang","year":"2008","unstructured":"Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137\u201362.","journal-title":"Osteoarthr Cartil"},{"key":"2815_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476\u201399.","journal-title":"Osteoarthr Cartil"},{"key":"2815_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","volume":"43","author":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update","year":"2000","unstructured":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905\u201315.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2815_CR8","doi-asserted-by":"publisher","first-page":"1900034","DOI":"10.1002\/adtp.201900034","volume":"2","author":"Anthony J. Hayes","year":"2019","unstructured":"Hayes AJ, Melrose J. Glycosaminoglycan and proteoglycan biotherapeutics in articular cartilage protection and repair strategies: novel approaches to visco-supplementation in orthobiologics. Adv Ther. 2019:1900034. \n                    https:\/\/doi.org\/10.1002\/adtp.201900034\n                    \n                   and references cited therein.","journal-title":"Advanced Therapeutics"},{"key":"2815_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1113\/jphysiol.1953.sp004842","volume":"119","author":"AG Ogston","year":"1953","unstructured":"Ogston AG, Stanier JE. The physiological function of hyaluronic acid in synovial fluid; viscous, elastic and lubricant properties. J Physiol. 1953;119:244\u201352.","journal-title":"J Physiol"},{"key":"2815_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1947603516684588","volume":"9","author":"RD Altman","year":"2018","unstructured":"Altman RD, Dasa V, Takeuchi J. Review of the mechanism of action for Supartz FX in knee osteoarthritis. Cartilage. 2018;9:11\u201320.","journal-title":"Cartilage."},{"key":"2815_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jbm.b.31971","volume":"100","author":"NE Larsen","year":"2012","unstructured":"Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100:457\u201362.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"2815_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/00003086-200402000-00021","volume":"419","author":"VM Goldberg","year":"2004","unstructured":"Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res. 2004;419:130\u20137.","journal-title":"Clin Orthop Relat Res"},{"issue":"7","key":"2815_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2106\/00004623-200207000-00008","volume":"84-A","author":"AL Chen","year":"2002","unstructured":"Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am. 2002;84-A(7):1142\u20137.","journal-title":"J Bone Joint Surg Am"},{"key":"2815_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jbspin.2003.09.006","volume":"71","author":"L Michou","year":"2004","unstructured":"Michou L, Job-Deslandre C, de Pinieux G, Kahan A. Granulomatous synovitis after intraarticular Hylan GF-20. A report of two cases. Joint Bone Spine. 2004;71:438\u201340.","journal-title":"Joint Bone Spine"},{"key":"2815_CR15","first-page":"53","volume":"15","author":"DD Waddell","year":"2006","unstructured":"Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv. 2006;15:53\u20139.","journal-title":"J Surg Orthop Adv"},{"key":"2815_CR16","first-page":"1311","volume":"22","author":"MP Puttick","year":"1995","unstructured":"Puttick MP, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995;22:1311\u20134.","journal-title":"J Rheumatol"},{"key":"2815_CR17","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1177\/0363546515609599","volume":"44","author":"RD Altman","year":"2016","unstructured":"Altman RD, Bedi A, Karlsson J, Sancheti P, Schemitsch E. Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. Am J Sports Med. 2016;44:2158\u201365.","journal-title":"Am J Sports Med"},{"key":"2815_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0008-6215(91)84095-V","volume":"218","author":"S Tanaka","year":"1991","unstructured":"Tanaka S, Aketagawa J, Takahashi S, Shibata Y, Tsumuraya Y, Hashimoto Y. Activation of a limulus coagulation factor G by (1\u21923)-\u03b2-D-glucan. Carbohydr Res. 1991;218:167\u201374.","journal-title":"Carbohydr Res"},{"key":"2815_CR19","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.joca.2014.08.002","volume":"22","author":"M Ishikawa","year":"2014","unstructured":"Ishikawa M, Yoshioka K, Urano K, Tanaka Y, Hatanaka T, Nii A. Biocompatibility of cross-linked hyaluronate (Gel-200) for the treatment of knee osteoarthritis. Osteoarthr Cartil. 2014;22:1902\u20139.","journal-title":"Osteoarthr Cartil"},{"key":"2815_CR20","first-page":"445","volume":"20","author":"A Schiavinato","year":"2002","unstructured":"Schiavinato A, Finesso M, Cortivo R, Abatangelo G. Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol. 2002;20:445\u201354.","journal-title":"Clin Exp Rheumatol"},{"key":"2815_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/00313020120083296","volume":"33","author":"IM Zerdawi","year":"2001","unstructured":"Zerdawi IM, Chan I. Synvisc perisynovitis. Pathology. 2001;33:519\u201320.","journal-title":"Pathology."},{"key":"2815_CR22","first-page":"655","volume":"32","author":"Y Ohshima","year":"2004","unstructured":"Ohshima Y, Yokota S, Kasama K, Ono H. Comparative studies of levels of proteins, bacterial endotoxins and nucleic acids in hyaluronan preparations used to treat osteoarthritis of the knee: could residual proteins and bacterial endotoxins relate to complications? Jpn Pharmacol Ther. 2004;32:655\u201362.","journal-title":"Jpn Pharmacol Ther"},{"key":"2815_CR23","unstructured":"Toxicolor\u2122 LS-50M kit package insert. \n                    http:\/\/www.lalbiz.com\/common\/frame\/plugins\/fileUD\/download.php?type=attached_pdf&p=020130.pdf&token=2dc929c2c54cafd7e544e5f8f347f193177542c0&t=20181005092439\n                    \n                  . Accessed 09 Sept 2019."},{"key":"2815_CR24","unstructured":"Glucatell package insert. \n                    http:\/\/www.acciusa.com\/pdfs\/accProduct\/pisheets\/Glucatell%20Insert%20English.pdf\n                    \n                  . Accessed 09 Sept 2019."},{"key":"2815_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/096805199500200309","volume":"2","author":"D Williams","year":"1995","unstructured":"Williams D, Mueller A, Browder W. Preclinical and clinical evaluation of carbohydrate immunopharmaceuticals in the prevention of sepsis and septic sequelae. J Endotoxin Res. 1995;2:203\u20138.","journal-title":"J Endotoxin Res"},{"key":"2815_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0162-3109(91)90039-2","volume":"22","author":"DL Williams","year":"1991","unstructured":"Williams DL, Pretus HA, McNamee RB, Jones EL, Ensley HE, Browder IW, et al. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology. 1991;22:139\u201356.","journal-title":"Immunopharmacology."},{"key":"2815_CR27","first-page":"605","volume":"211","author":"W Browder","year":"1990","unstructured":"Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg. 1990;211:605\u201313.","journal-title":"Ann Surg"},{"key":"2815_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/pat.1994.220050910","volume":"5","author":"D Williams","year":"1994","unstructured":"Williams D, Browder W. Development of natural product (1\u21923)-\u03b2-D-glucan polymers as immune stimulating pharmaceuticals. Polymer Adv Tech. 1994;5:529\u201334.","journal-title":"Polymer Adv Tech"},{"key":"2815_CR29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00262-016-1875-9","volume":"65","author":"C Barton","year":"2016","unstructured":"Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax HJ, et al. Beta-glucan contamination of pharmaceutical products: how much should we accept? Cancer Immunol Immunother. 2016;65:1289\u2013301.","journal-title":"Cancer Immunol Immunother"},{"key":"2815_CR30","unstructured":"Sandle T. Pharmaceutical product impurities: considering beta glucans. Am Pharm Rev. Posted 31 August, 2013. \n                    http:\/\/www.americanpharmaceuticalreview.com\/Featured-Articles\/152953-Pharmaceutical-Product-Impurities-Considering-Beta-Glucans\/\n                    \n                  . Accessed 09 Sept 2019."},{"key":"2815_CR31","first-page":"1413","volume":"44","author":"A Nakao","year":"1997","unstructured":"Nakao A, Yasui M, Kawagoe T, Tamura H, Tanaka S, Takagi H. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology. 1997;44:1413\u20138.","journal-title":"Hepatogastroenterology."},{"key":"2815_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1046\/j.1537-2995.2002.00162.x","volume":"42","author":"M Usami","year":"2002","unstructured":"Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1\u21923)-beta-D-glucan in blood components and release of (1\u21923)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion. 2002;42:1189\u201395.","journal-title":"Transfusion."},{"key":"2815_CR33","unstructured":"ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances, October 1999. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q6A\/Step4\/Q6Astep4.pdf\n                    \n                  . Accessed 7 Sept 2018."},{"key":"2815_CR34","unstructured":"ICH Q6B \n                    specifications: test procedures and acceptance criteria for biotechnological\/biological products\n                    \n                  , March 1999. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q6B\/Step4\/Q6B_Guideline.pdf\n                    \n                  . Accessed 7 Sept 2018."}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-019-2815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-019-2815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-019-2815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:16:17Z","timestamp":1599779777000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-019-2815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1186\/s12891-019-2815-6","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Seikagaku Corporation and performed under the animal husbandry\/management system in an appropriate environment, with animal protection\/welfare in mind.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Yoshioka, M. Katayama, T. Nishiyama, K. Harada, S. Takeshita, and Y. Kawamata are employees of the Seikagaku Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"424"}}